


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

- 1. (original):** An antidepressant comprising, as an active ingredient, a compound having an antagonistic effect on group II metabotropic glutamate receptors.
- 2. (currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [I]:



[wherein

R¹ and R², which may be the same or different, each represent a hydroxyl group, a C₁₋₁₀ alkoxy group, a phenoxy group, a naphthyloxy group, a C₁₋₆ alkoxy group which is substituted with one or two phenyl groups, a C₁₋₆ alkoxy-C₁₋₆ alkoxy group, a hydroxy-C₂₋₆ alkoxy group, an amino group, an amino group which is substituted with the same or different one or two C₁₋₆ alkyl groups, an amino group which is substituted with the same or different one or two C₁₋₆ alkoxy-C₁₋₆ alkyl groups, an amino group which is substituted with the same or different one or two hydroxy-C₂₋₆ alkyl groups, an amino group which is substituted with the same or different one or two C₁₋₆ alkoxycarbonyl-C₁₋₆ alkyl groups, or a native or non-native amino acid residue

represented by $\text{NR}^6\text{-CHR}^7\text{-A-CO}_2\text{R}^8$ (wherein R^6 and R^7 , which may be the same or different, each represent a hydrogen atom, a hydroxy- C_{1-6} alkyl group, a hydroxycarbonyl- C_{1-6} alkyl group, a C_{1-10} alkyl group, a phenyl group, a phenyl- C_{1-6} alkyl group, a hydroxyphenyl group, a hydroxyphenyl- C_{1-6} alkyl group, a naphthyl group, a naphthyl- C_{1-6} alkyl group, an aromatic heterocyclic C_{1-6} alkyl group, a C_{1-6} alkoxy- C_{1-6} alkyl group, an amino- C_{2-6} alkyl group, a guanidino- C_{2-6} alkyl group, a mercapto- C_{2-6} alkyl group, a C_{1-6} alkylthio- C_{1-6} alkyl group or an aminocarbonyl- C_{1-6} alkyl group, or R^6 and R^7 may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; R^8 represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

R^3 represents a hydrogen atom, a C_{1-10} acyl group, a C_{1-6} alkoxy- C_{1-6} acyl group, a hydroxy- C_{2-10} acyl group, a C_{1-6} alkoxycarbonyl- C_{1-6} acyl group, a hydroxycarbonyl- C_{1-6} acyl group, or an amino acid residue represented by $\text{R}^9\text{-NH-A-CHR}^7\text{-CO}$ (wherein R^7 and A are as defined above, and R^9 represents a hydrogen atom or a protecting group for an amino group); and

R^4 and R^5 , which may be the same or different, each represent a hydrogen atom, a C_{1-10} alkyl group, a C_{2-10} alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a C_{1-10} alkyl group, a C_{1-10} alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or R^4 and R^5 may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.


3. **(original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], R^1 and R^2 are each a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

4. **(original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], R^1 is a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

5. **(original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], R^2 is a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

6. **(original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], R^1 and R^2 are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

7. **(currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [II]:



[wherein

R^1 and R^2 , which may be the same or different, each represent a hydroxyl group, a C_{1-10} alkoxy group, a phenoxy group, a naphthyloxy group, a C_{1-6} alkoxy group which is substituted with one or two phenyl groups, a C_{1-6} alkoxy- C_{1-6} alkoxy group, a hydroxy- C_{2-6} alkoxy group, an amino group, an amino group which is substituted with the same or different one or two C_{1-6} alkyl groups, an amino group which is substituted with the same or different one or two C_{1-6} alkoxy- C_{1-6} alkyl groups, an amino group which is substituted with the same or different one or two hydroxy- C_{2-6} alkyl groups, an amino group which is substituted with the same or different one or two C_{1-6} alkoxycarbonyl- C_{1-6} alkyl groups, or a native or non-native amino acid residue represented by $NR^6-CHR^7-A-CO_2R^8$ (wherein R^6 and R^7 , which may be the same or different, each represent a hydrogen atom, a hydroxy- C_{1-6} alkyl group, a hydroxycarbonyl- C_{1-6} alkyl group, a C_{1-10} alkyl group, a phenyl group, a phenyl- C_{1-6} alkyl group, a hydroxyphenyl group, a hydroxyphenyl- C_{1-6} alkyl group, a naphthyl group, a naphthyl- C_{1-6} alkyl group, an aromatic heterocyclic C_{1-6} alkyl group, a C_{1-6} alkoxy- C_{1-6} alkyl group, an amino- C_{2-6} alkyl group, a guanidino- C_{2-6} alkyl group, a mercapto- C_{2-6} alkyl group, a C_{1-6} alkylthio- C_{1-6} alkyl group or an aminocarbonyl- C_{1-6} alkyl group, or R^6 and R^7 may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; R^8 represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

R^3 represents a hydrogen atom, a C_{1-10} acyl group, a C_{1-6} alkoxy- C_{1-6} acyl group, a hydroxy- C_{2-10} acyl group, a C_{1-6} alkoxycarbonyl- C_{1-6} acyl group, a hydroxycarbonyl- C_{1-6} acyl group, or an amino acid residue represented by $R^9-NH-A-CHR^7-CO$ (wherein R^7 and A are as

defined above, and R⁹ represents a hydrogen atom or a protecting group for an amino group);
and

R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₁₀ alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a C₁₋₁₀ alkyl group, a C₁₋₁₀ alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or R⁴ and R⁵ may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.

8. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R¹ and R² are each a hydroxyl group and R³ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

9. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R¹ is a hydroxyl group and R³ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

10. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R¹ is a hydroxyl group, R³ is a hydrogen atom, and R² is a C₁₋₁₀ alkoxy group or a C₁₋₆ alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

11. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^1 is a hydroxyl group, R^3 is a hydrogen atom, and R^2 is $NH-CHR^7-CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

12. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^2 is a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.


13. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^2 is a hydroxyl group, R^3 is a hydrogen atom, and R^1 is a C_{1-10} alkoxy group or a C_{1-6} alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

14. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^2 is a hydroxyl group, R^3 is a hydrogen atom, and R^1 is $NH-CHR^7-CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

15. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^1 and R^2 are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

16. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], R^1 and R^2 are each a hydroxyl group and R^3 is H_2N-CHR^7-CO , or a pharmaceutically acceptable salt or hydrate thereof.

17. **(currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [III]:



[wherein

R¹ and R², which may be the same or different, each represent a hydroxyl group, a C₁₋₁₀ alkoxy group, a phenoxy group, a naphthyloxy group, a C₁₋₆ alkoxy group which is substituted with one or two phenyl groups, a C₁₋₆ alkoxy-C₁₋₆ alkoxy group, a hydroxy-C₂₋₆ alkoxy group, an amino group, an amino group which is substituted with the same or different one or two C₁₋₆ alkyl groups, an amino group which is substituted with the same or different one or two C₁₋₆ alkoxy-C₁₋₆ alkyl groups, an amino group which is substituted with the same or different one or two hydroxy-C₂₋₆ alkyl groups, an amino group which is substituted with the same or different one or two C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkyl groups, or a native or non-native amino acid residue represented by NR⁶-CHR⁷-A-CO₂R⁸ (wherein R⁶ and R⁷, which may be the same or different, each represent a hydrogen atom, a hydroxy-C₁₋₆ alkyl group, a hydroxycarbonyl-C₁₋₆ alkyl group, a C₁₋₁₀ alkyl group, a phenyl group, a phenyl-C₁₋₆ alkyl group, a hydroxyphenyl group, a hydroxyphenyl-C₁₋₆ alkyl group, a naphthyl group, a naphthyl-C₁₋₆ alkyl group, an aromatic heterocyclic C₁₋₆ alkyl group, a C₁₋₆ alkoxy-C₁₋₆ alkyl group, an amino-C₂₋₆ alkyl group, a guanidino-C₂₋₆ alkyl group, a mercapto-C₂₋₆ alkyl group, a C₁₋₆ alkylthio-C₁₋₆ alkyl group or an

aminocarbonyl-C₁₋₆ alkyl group, or R⁶ and R⁷ may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; R⁸ represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

R³ represents a hydrogen atom, a C₁₋₁₀ acyl group, a C₁₋₆ alkoxy-C₁₋₆ acyl group, a hydroxy-C₂₋₁₀ acyl group, a C₁₋₆ alkoxycarbonyl-C₁₋₆ acyl group, a hydroxycarbonyl-C₁₋₆ acyl group, or an amino acid residue represented by R⁹-NH-A-CHR⁷-CO (wherein R⁷ and A are as defined above, and R⁹ represents a hydrogen atom or a protecting group for an amino group); and

R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom, a C₁₋₁₀ alkyl group, a C₂₋₁₀ alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a C₁₋₁₀ alkyl group, a C₁₋₁₀ alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or R⁴ and R⁵ may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.

18. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R¹ and R² are each a hydroxyl group and R³ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

19. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^1 is a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

20. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^1 is a hydroxyl group, R^3 is a hydrogen atom, and R^2 is a C_{1-10} alkoxy group or a C_{1-6} alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

21. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^1 is a hydroxyl group, R^3 is a hydrogen atom, and R^2 is $NH-CHR^7-CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

22. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^2 is a hydroxyl group and R^3 is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

23. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^2 is a hydroxyl group, R^3 is a hydrogen atom, and R^1 is a C_{1-10} alkoxy group or a C_{1-6} alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

24. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^2 is a hydroxyl group, R^3 is a hydrogen atom, and R^1 is $HN-CHR^7-CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

25. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^1 and R^2 are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

26. (original): The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], R^1 and R^2 are each a hydroxyl group and R^3 is NH_2-CHR^7-CO , or a pharmaceutically acceptable salt or hydrate thereof.

27. (original): A pharmaceutical preparation comprising one or more pharmaceutically acceptable carriers, excipients or diluents and the compound according to any one of claims 2 to 26.

28. (original): A drug comprising the compound according to any one of claims 2 to 26 as an active ingredient.

29. (original): The drug according to claim 28, which is an antagonist of group II metabotropic glutamate receptors.

30. (original): The use of the compound according to any one of claims 2 to 26 as a drug.